Cannabis
Canopy Growth bought out its competition to consolidate leadership
Canopy Growth announced the acquisition of one of its main rivals, Supreme Cannabis, in a transaction valued at $345.6 million (CA$435 million). The purchase of Supreme Cannabis also provides Canopy Growth with a new source of low-cost cannabis. In addition to cannabis, Canopy has products in the health and nutrition sectors in Canada, the U.S. and Europe through the BioSteel brand.
Canopy Growth, one of the world’s largest cannabis producers, announced Thursday the purchase of one of its main rivals, Supreme Cannabis, in a deal valued at $ 345.6 million (CA$435 million), to consolidate its position in Canada.
In this country, recreational cannabis consumption has been legal since the end of 2018.
The acquisition will mean that Supreme Cannabis shareholders will receive for each of their shares 0.0116 Canopy Growth shares and $0.0001, which is 66% more than the closing value of the shares on April 7th.
Cannabis is one of the world’s most talked-about topics and the Hemp.im cannabis news application focuses on the latest news, social change, economic trends, and medical information in the industry. As your official hemp news app, the app also covers salient topics like the Hemp Farm Bill, the legality of cannabis, the various health benefits of CBD as well as the multitude of products made from hemp.
Canopy Growth said in a statement that the transaction will benefit both companies.
Thus, on the one hand, “Canopy will own a strengthened range of brands including one of Canada’s leading high-end brands, 7ACRES.” On the other hand, “Supreme Cannabis shareholders will benefit from Canopy’s CBD (cannabidiol) business in the United States,” the note added.
The CBD sector, a compound from hemp and cannabis plants that is increasingly used as a dietary supplement, is experiencing rapid growth in the U.S. since the legalization of cannabidiol in 2018.
In addition to cannabis, Canopy has products in the health and nutrition sectors in Canada, the U.S. and Europe through the BioSteel brand.
The purchase of Supreme Cannabis also provides Canopy Growth with a new source of low-cost cannabis, thanks to the company’s hybrid greenhouse in the Canadian town of Kincardine that “has demonstrated the ability to consistently produce high-quality flower of high-demand strains at a low cost and with significant growth potential.”
David Klein, Canopy’s CEO, welcomed the fact that the company will reach more consumers with Supreme’s high-end brands and high-quality products, which will strengthen its leadership.
For her part, Beena Goldenberg, the president of Supreme Cannabis, stressed that this transaction will be beneficial for all stakeholders of the company.
The deal has to be approved by the courts as well as by two-thirds of the votes cast by Supreme’s shareholders at a special shareholders’ meeting to be held in June this year.
__
(Featured image by PublicDomainPictures via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in negocios, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Biotech2 weeks ago
Rovi Cuts Its Profit by 4% in the First Nine Months, to 113.5 Million
-
Biotech3 days ago
Better Care Advances Healthcare Technology with Partnership with Oracle
-
Fintech1 week ago
Fintech Company Satispay Raises 60 Million Euros Led by Addition
-
Biotech1 day ago
ATB Therapeutics Raises €54 Million and Attracts a Pharmaceutical Giant